Eyal Morag - 01 Aug 2023 Form 4 Insider Report for Microbot Medical Inc. (MBOT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Aug 2023, 16:30:42 UTC
Prior SEC filing
19 Jan 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Eyal Morag

Key filing fact

Eyal Morag filed Form 4 for Microbot Medical Inc. (MBOT) on 03 Aug 2023.

Key facts

  • This page summarizes Eyal Morag's Form 4 filing for Microbot Medical Inc. (MBOT).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 03 Aug 2023, 16:30.

Change

  • Previous filing in this sequence was filed on 19 Jan 2023.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MBOT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+17,500
Change %
Price
$0.000000
Shares after
17,500
Date
01 Aug 2023
Ownership
Direct
Underlying class
Common Stock, par value $0.01 per share
Underlying amount
17,500
Exercise price
$2.43
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options vest as follows and in accordance with the terms of the Issuer's 2020 Omnibus Performance Award Plan (the "Plan"): (a) on February 1, 2024, the option shall vest and shall become exercisable with respect to 25% of the common stock; and (b) on a quarterly basis over the next 30 months, the option shall equally vest and become exercisable with respect to the remaining 75% of the common stock, subject to acceleration pursuant to the terms of the Plan.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .